Home›Articles›From a one-year trial to a 2023 approval for Fabry diseaseArticleFrom a one-year trial to a 2023 approval for Fabry diseaseArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnPegunigalsidase alfa, Drugs and Medicinal Substances Well-attested SourcesPegunigalsidase alfa (Wikipedia)Society and culture, Legal statusQuote, Society and culture, Legal statusIn February 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Elfabrio, intended for the treatment of Fabry disease.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.